for an excellent first-hand take into the challenge of building ai-first bio companies, please read @agupta
’s essay “how unfair is the coin” in it he discusses:
– why selling software to pharma isn’t really a market – why software-only in bio ultimately converges to “make

→ View original post on X — @nathanbenaich,